Although model-based solution strategies for the ECGI were reported to deliver promising clinical results, they strongly rely on some a priori assumptions, which do not hold true for many pathological cases. The fastest route algorithm (FRA) is a well-established method for noninvasive imaging of ectopic activities. It generates test activation sequences on the heart and compares the corresponding test body surface potential maps (BSPMs) to the measured ones. The test excitation propagation patterns are constructed under the assumption of a global conduction velocity in the heart, which is violated in the cardiac resynchronization (CRT) patients suffering from conduction disturbances. In the present work, we propose to apply dynamic time warping (DTW) to the test and measured ECGs before measuring their similarity. The warping step is a non-linear pattern matching that compensates for local delays in the temporal sequences, thus accounting for the inhomogeneous excitation propagation, while aligning them in an optimal way with respect to a distance function. To evaluate benefits of the temporal warping for FRA-based BSPMs, we considered three scenarios. In the first setting, a simplified simulation example was constructed to illustrate the temporal warping and display the resulting distance map. Then, we applied the proposed method to eight BSPMs produced by realistic ectopic activation sequences and compared its performance to FRA. Finally, we assessed localization accuracy of both techniques in ten CRT patients. For each patient, we noninvasively imaged two paced ECGs: from left and right ventricular implanted leads. In all scenarios, FRA-DTW outperformed FRA in terms of LEs. For the clinical cases, the median (25-75% range) distance errors were reduced from 16 (8-23)mm to 5 (2-10)mm for all pacings, from 15 (11-25)mm to 8 (3-13)mm in the left, and from 19 (6-23)mm to 4 (2-8)mm in the right ventricle, respectively. The obtained results suggest the ability of temporal ECG warping to compensate for an inhomogeneous conduction profile, while retaining computational efficiency intrinsic to FRA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421262PMC
http://dx.doi.org/10.3389/fphys.2019.00183DOI Listing

Publication Analysis

Top Keywords

crt patients
12
fastest route
8
route algorithm
8
activation sequences
8
excitation propagation
8
temporal warping
8
warping
5
ecg adapted
4
adapted fastest
4
algorithm localize
4

Similar Publications

Purpose: Current management for clinically localized prostate cancer in low- and middle-income countries (LMICs) includes surgery, external beam radiation therapy (EBRT), and brachytherapy either alone or in combination, with plus or minus hormone therapy. The toxicity profiles and oncological outcomes of these treatment modalities vary. This systematic review and meta-analysis aimed to determine the prevalence of treatment-related outcomes and toxicities for men diagnosed with localized prostate cancer in LMICs.

View Article and Find Full Text PDF

Introduction: Chemoradiation followed by durvalumab is considered a standard approach for patients with locally advanced NSCLC. With improvements in perioperative and neoadjuvant approaches, there is renewed interest in offering surgery to carefully selected patients with cT3/4N2 stage IIIB cancer. We sought to assess survival outcomes after surgery as part of a multimodality treatment regimen for these patients.

View Article and Find Full Text PDF

Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases.

Methods: This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible.

View Article and Find Full Text PDF

Longitudinal circulating tumor DNA monitoring in predicting response to short-course radiotherapy followed by neoadjuvant chemotherapy and camrelizumab in locally advanced rectal cancer: data from a Phase Ⅲ clinical trial (UNION).

Cancer Lett

January 2025

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Precision Radiation Oncology, Wuhan 430022, China. Electronic address:

This study, conducted as part of a multicenter phase III clinical trial, aimed to assess the utility of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) in comparing the efficacy of short-course and long-course chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). A total of 244 plasma samples from 79 LARC patients undergoing neoadjuvant therapy (NAT) before surgery were collected at various time points. Targeted deep sequencing using a novel MRD panel was performed.

View Article and Find Full Text PDF

Defining the optimal radiation-induced lymphopenia metric to discern its survival impact in esophageal cancer.

Int J Radiat Oncol Biol Phys

January 2025

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, United States of America; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands.

Background: A detrimental association between radiation-induced lymphopenia (RIL) and oncologic outcomes in esophageal cancer patients has been established. However, an optimal metric for RIL remains undefined, but is important for application of this knowledge in clinical decision-making and trial designs. The aim of this study was to find the optimal RIL metric discerning survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!